Literature DB >> 3006346

Oncogenic retrovirus from spontaneous murine osteomas. II. Molecular cloning and genomic characterization.

C Leib-Mösch, J Schmidt, M Etzerodt, F S Pedersen, R Hehlmann, V Erfle.   

Abstract

An N-ecotropic murine leukemia virus (OA MuLV), originally isolated from spontaneous osteomas of strain 101 mice, was molecularly cloned. The virus induces osteomas, osteopetrosis, and malignant lymphomas in NMRI mice. The cloned virus was analyzed by heteroduplex analysis, restriction enzyme mapping, and oligonucleotide mapping. The data show a very close relationship to the endogenous Akv prototype virus with some differences in the gag and the env region. The nucleotide sequence of the U3 region of OA MuLV LTR revealed a structure within the presumable enhancer region very similar to the U3 sequences of the FBJ murine sarcoma virus and its associated helper virus. The significance of these specific structures for the oncogenicity of the virus and the development of the typical disease pattern is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006346     DOI: 10.1016/0042-6822(86)90269-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.

Authors:  S Ethelberg; B D Tzschaschel; A Luz; S J Diaz-Cano; F S Pedersen; J Schmidt
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  Retrovirus-induced osteopetrosis in mice. Effects of viral infection on osteogenic differentiation in skeletoblast cell cultures.

Authors:  J Schmidt; M Casser-Bette; A B Murray; A Luz; V Erfle
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

3.  SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.

Authors:  B Hallberg; J Schmidt; A Luz; F S Pedersen; T Grundström
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Control of pathogenicity and disease specificity of a T-lymphomagenic gammaretrovirus by E-box motifs but not by an overlapping glucocorticoid response element.

Authors:  Ditte Ejegod; Karina Dalsgaard Sørensen; Ilona Mossbrugger; Leticia Quintanilla-Martinez; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

6.  Enhancer functions in U3 of Akv virus: a role for cooperativity of a tandem repeat unit and its flanking DNA sequences.

Authors:  S Lovmand; N O Kjeldgaard; P Jørgensen; F S Pedersen
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

7.  Effects of leukemogenic retroviruses on condylar cartilage in vitro: an ultrastructural study.

Authors:  E Livne; J Schmidt; E I Closs; M Silbermann; V Erfle
Journal:  Calcif Tissue Int       Date:  1989-01       Impact factor: 4.333

8.  Onset and dynamics of osteosclerosis in mice induced by Reilly-Finkel-Biskis (RFB) murine leukemia virus. Increase in bone mass precedes lymphomagenesis.

Authors:  J Schmidt; K Lumniczky; B D Tzschaschel; H L Guenther; A Luz; S Riemann; W Gimbel; V Erfle; R G Erben
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

9.  Retrovirus-induced osteopetrosis in mice. Ultrastructural evidence of early virus production in osteoblasts and osteocytes.

Authors:  A B Murray; J Schmidt; L Rieke
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

10.  Molecular cloning of osteoma-inducing replication-competent murine leukemia viruses from the RFB osteoma virus stock.

Authors:  L Pedersen; W Behnisch; J Schmidt; A Luz; F S Pedersen; V Erfle; P G Strauss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.